{"id":400097,"date":"2020-12-15T10:03:08","date_gmt":"2020-12-15T15:03:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400097"},"modified":"2020-12-15T10:03:08","modified_gmt":"2020-12-15T15:03:08","slug":"dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/","title":{"rendered":"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEWTON, Mass., Dec.  15, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_ACgv5zo30VqB8g4oxxHbUS5W1IiKNuAeZy4GDiHfU902IypnwU-gshxnkdyk_wm1UnN2t6ukCSF6whYSJfIRQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">4D Path<\/a>, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company\u2019s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare.<\/p>\n<p>Dr. Carter is managing director of JLC Precision Health Strategies, LLC., which partners with executives and investors to advise data-driven healthcare and life science companies on their commercial and financing strategy, and on the development of novel products and services. Previously, she was founder and CEO of TrialzOWN, Inc., a healthcare company in stealth that was acquired by Integral Health (now Valo Health) in March 2019. Prior to TrialzOWN, Dr. Carter was the founder and president of N-of-One<sup>\u00ae<\/sup>, Inc. At N-of-One, Dr. Carter led the creation of award-winning solutions that delivered novel treatment strategies to hundreds of thousands of patients with cancer globally. She served as acting-CEO from 2008-2012, and chief medical officer from 2012 until its acquisition by Qiagen (Market Cap $8B) in 2019.<\/p>\n<p>4D Path, which has raised $6.4 million in funding to date and been awarded a coveted <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=th5p_oHmhUB9NkjjpYpZq9W14KhL8SNVwYaHrJXEEzooGTLI9WrzQTR9ojEdj4fogQTazF8hZK6B6tMId2FUDK4_0hHGwP_zDlmpAVYRDB27HVS8QpBDB_Vnrb_ai0TGQZQSgimJkya2O1KeNLAVoBLf5H5oASOnTd_z5NTT7eQq8_pDPTdIpm57yng957XTAsXVNvdRohQ7e__WL_MK2A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">FDA Breakthrough Device Designation<\/a>, applies a cloud-based, quantitative approach to finding the data previously hidden in H&amp;E biopsy and resection images without adding extra load to the current standard of care. As a result, the initial biopsy will no longer be the first step in a lengthy process towards biomarker profiling and stratification, but perhaps the only step necessary without the need for additional molecular tests (e.g. immunohistochemistry, FISH, RNA-Seq, NGS).<\/p>\n<p>\u201cI am excited about 4D Path\u2019s novel way of providing molecular decision support and patient specific insights\u00a0to targeted therapy\u00a0based on\u00a0both\u00a0a single H&amp;E slide as well as from all the H&amp;E slides available per patient,\u201d said Dr Carter. \u201c4D Path\u2019s ability to read pan-cancer biologic signatures of the underlying\u00a0molecular drivers\u00a0hidden in the H&amp;E-stained tissue images\u00a0is powerful and unique. This\u00a0capability\u00a0can potentially add an extra dimension to the current genome-based molecular screening methods\u00a0that may bring the power of genomics to more patients fighting cancer quicker and at lower cost.\u201d<\/p>\n<p>Just from whole slide H&amp;E biopsy\/resection images, in seconds 4D Path can identify cancer type, its pan-cancer prognostically significant molecular subtypes, grades, and molecular profile with overexpression status as well as benign lesions. Its accelerated and more accurate diagnostic tool is commercially available now for use in clinical trials to allow pharmaceutical and biopharmaceutical companies to efficiently focus more precisely on effective treatments and targeted therapies.<\/p>\n<p>\u201cWe are thrilled to have an entrepreneur, executive and thought leader of Dr. Carter\u2019s caliber join our established team of esteemed advisory board members,\u201d said Rodrigo Navarro, president and CEO, 4D Path. \u201cHer expertise will be invaluable as we navigate the company\u2019s next steps towards market adoption and strategy towards pharmaceuticals \u2013 highlighting 4D Path\u2019s ability to reduce cost, time and complexity of clinical trials and patient management.\u201d<\/p>\n<p>As the latest addition to 4D Path\u2019s advisory board, Dr. Carter joins a distinguished team of scientists, clinicians and management from world-leading research institutions, including Barry Fogel M.D. \u2013 Harvard School of Medicine, Professor Donald Lessard \u2013 MIT Sloan School of Management, and Judy C. Lewent \u2013 Former Executive Vice President &amp; Chief Financial Officer, Merck &amp; Co.<\/p>\n<p>Dr. Carter graduated Phi Beta Kappa, Summa Cum Laude with distinction with a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School at Massachusetts Institute of Technology.<\/p>\n<p>\n        <strong>About 4D Path<\/strong><br \/>\n        <br \/>Just because you can\u2019t see something, doesn\u2019t mean it\u2019s not there. 4D Path\u2019s patented precision oncology platform is designed to unveil previously hidden data to instantly provide biomarker profiling and stratification directly from H&amp;E whole slide biopsy\/resection images only. 4D Path\u2019s cloud-based, quantitative approach is intended to eliminate the need for additional molecular tests (e.g., immunohistochemistry, FISH, RNA-Seq, NGS), accelerating complete, actionable and objective insight leading to expedited and democratized precision medicine. 4D Path\u2019s quantitative approach is designed to provide clinical solutions in both companion diagnostics and translational medicine without compromising the current standard of care to reduce the cost, time and complexity of patient care and management, and clinical trials. Its patented methods and integrated platform combine universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints in order to inform treatment selection and stratify patients accordingly. Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DhF0aPEG3C9bqmkBGAoeXG1AOq4dlF8eaq4-wQ6FrmQ-D-py3CfhzvcSplnOxAhaRIDXF8IYOUbMFTRsqMWsFA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.4DPath.com<\/a> to learn more.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7d3e6cbc-4b1b-472a-a643-6bc3f7ce6e1a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>PR Contact\r\nJordan Bouclin\r\nSVM PR &amp; Marketing Communications\r\nJordan.bouclin@svmpr.com\r\n(401)490-9700<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company\u2019s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare. Dr. Carter is managing director of JLC Precision Health Strategies, LLC., which partners with executives and investors to advise data-driven healthcare and life science companies on their commercial and financing strategy, and on the development of novel products and services. Previously, she was founder and CEO of TrialzOWN, Inc., a healthcare company in stealth that was acquired &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400097","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company\u2019s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare. Dr. Carter is managing director of JLC Precision Health Strategies, LLC., which partners with executives and investors to advise data-driven healthcare and life science companies on their commercial and financing strategy, and on the development of novel products and services. Previously, she was founder and CEO of TrialzOWN, Inc., a healthcare company in stealth that was acquired &hellip; Continue reading &quot;Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T15:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path\",\"datePublished\":\"2020-12-15T15:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/\"},\"wordCount\":797,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/\",\"name\":\"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=\",\"datePublished\":\"2020-12-15T15:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path - Market Newsdesk","og_description":"NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company\u2019s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare. Dr. Carter is managing director of JLC Precision Health Strategies, LLC., which partners with executives and investors to advise data-driven healthcare and life science companies on their commercial and financing strategy, and on the development of novel products and services. Previously, she was founder and CEO of TrialzOWN, Inc., a healthcare company in stealth that was acquired &hellip; Continue reading \"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T15:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path","datePublished":"2020-12-15T15:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/"},"wordCount":797,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/","name":"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=","datePublished":"2020-12-15T15:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjA3OCMzODgxMTI3IzIyMDQ1Mzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-jennifer-levin-carter-joins-advisory-board-of-novel-precision-oncology-platform-creator-4d-path\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400097"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400097\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}